Skip to Content

Pfizer

Pfizer slipped a few spots, in large part because of the expiration last year of one of its more lucrative patents, for the fibromyalgia drug Lyrica. That eroded the drugmaker's revenue, which fell 4% overall in 2019. But Pfizer also made some big moves: After years of rumors that it would split up, Pfizer finally slimmed down, announcing over the summer that it would merge Upjohn, its off-patent drug division, with general drug company Mylan. Meanwhile, the pharmaceutical giant found some significant efficiencies in its operations: profits surged some 46%.
Daniel Acker—Bloomberg via Getty Images
Lists ranking Pfizer
RANK64
Fortune 500 - 2020This year's Fortune 500 marks the 66th running of ...READ MORE
World’s Most Admired Companies - 2020For an astounding 13th straight year, Apple claims...READ MORE
Created with sketchtool.Created with sketchtool.Leads, insights, and financial data for the FORTUNE 500, FORTUNE 1000, and Global 500 companies.Purchase Now